Skip to main content

Home/ MaRS/ Group items tagged commercialization tenants

Rss Feed Group items tagged

Assunta Krehl

The Centre for Commercialization of Regenerative Medicine (CCRM): CCRM Announces Its In... - 0 views

  •  
    Rafi Hofstein, President and CEO of MaRS Innovation is one of the inaugural Board of Directors for The Centre for Commercialization of Regenerative Medicine (CCRM). CCRM is a MaRS tenant.
Assunta Krehl

OGI and MaRS Innovation invest in peptide therapeutics - Eurek Alert - September 28, 2011 - 0 views

  •  
    As stated by Alastair Harris-Cartwright "Dr. Andrei Yudin, Professor, Department of Chemistry, University of Toronto, has developed a new and effective process that makes linear peptides circular, which allows these molecules, called macrocycles, to enter cells more effectively and increase their stability compared to linear peptides." The Ontario Genomics Institute (OGI) a MaRS Tenant has invested in this project. The project is also supported by MaRS Innovation that is assisting to convert this "great science into commercial opportunities."
Assunta Krehl

Test-tube industry - Canadian Business - 0 views

  • For Dr. John Evans, growing a strong biotechnology industry is much the same: cities must provide a nurturing environment where science and business can thrive together.
  • That's why Evans, former president of the University of Toronto and current chairman of Torstar Corp., is spearheading the $345-million Medical and Related Science initiative, or MaRS--a petri dish of sorts for commercializing science research. "A lot of intellectual property is being commercialized outside Canada," says Evans. "I think we've been slow in realizing just how important technology developments are to the economic future of the country. MaRS is an attempt to give this a kick into a higher gear." The centrepiece of the MaRS plan, which will officially launch May 12, is a 1.3-million-square-foot, five-building complex in downtown Toronto that will provide office and lab space for small and medium-size companies and incubators, including the not-for-profit Toronto Biotechnology Commercialization Centre. While Evans is reluctant to limit its scope, MaRS will generally focus on health-related technologies, from new drugs and genetic treatments to medical devices and imaging software. Branded a "convergence centre," it will also house a careful mix of support services: intellectual property lawyers, accountants, marketing experts, government funding organizations and venture capital financiers. Plus, start-ups will have access to all the latest equipment on site. For instance, MaRS is in talks with MDS Sciex to supply mass spectrometers, used in proteomics research.
  • But MaRS will be more than just a New Economy real estate development. Evans's intention is to funnel tenants' rent money into services--such as entrepreneurship seminars and angel-matching programs--that MaRS will offer to the broader biotech community. That's why MaRS's location is key: the centre will be built in the heart of what Toronto has dubbed the "Discovery District," a two-square-kilometre chunk of the downtown core, encompassing U of T and four major hospitals. From there, MaRS hopes to act as a network hub across Ontario, with links to research-intensive universities. "None of them," says Evans, "have the critical mass to put it all together on their own."
  • ...3 more annotations...
  • MaRS's primary goal is to get Toronto and the rest of Ontario on the global biotech map. Evans came up with the concept in the late 1990s with Dr. Calvin Stiller, CEO of the labor-sponsored Canadian Medical Discoveries Fund, and Kenneth Knox, a former deputy minister for the Ontario government who's now CEO of MaRS
  • As far as schemes to support fledgling industries go, MaRS is refreshing. To start, it's a nonprofit corporation, not a government program, which will hopefully ensure that it runs more efficiently. The feds and the province of Ontario have each doled out $20 million for MaRS, and Toronto has donated in-kind $4.5 million. More than $12 million has come from a small pool of corporations, including Eli Lilly Canada and MDS, as well as individual donors like Joseph Rotman and Lawrence Bloomberg (who both sit on the MaRS board). U of T pitched in $5 million, and MaRS also did some innovative bond financing to round off the $165 million needed to build Phase I. "It was very important for us to not belong to anybody," says Evans.
  • Now MaRS's challenge is to get the word out. Its posted rate of $26 per square foot is very competitive for prime downtown real estate and is sure to attract attention, especially considering its customized lab space. But MaRS's success won't be measured by a low vacancy rate; getting the right mix of scientists, entrepreneurs and professionals is critical if it plans to commercialize some sustainable businesses. It won't happen overnight--in fact, it may be 10 years before anyone can gauge MaRS's impact. Seems growing a biotech industry isn't quite as easy as growing E. coli in a petri dish.
  •  
    John Evans spearheads the MaRS project which will help to accelerate commercialization for scientific research. The official launch of the MaRS plan will happen on May 12, 2003.
Assunta Krehl

Commercializing R&D to be a key focus in federal budget - Global News - March 27, 2012 - 0 views

  •  
    Commercialization is a challenge for Canada's research and development sector. MaRS innovation states "Financing continues to be a major obstacle for Canada's emerging young innovators."
Assunta Krehl

Ontario Institute for Cancer Research Plans Hires, Increased Commercial Activities - Ge... - 0 views

  •  
    The Ontario Institute for Cancer Research in 2010 will grow its workforce, step up efforts to commercialize discoveries, and aim to fulfill research goals to be detailed in a second strategic plan set to be submitted next month to provincial officials, according to the institute's president and scientific director, Tom Hudson.
Assunta Krehl

Medical lab operator CML HealthCare outlines strategy for growth, innovation - 680News ... - 0 views

  •  
    CML HealthCare Inc is planning to automate it's current infrastructure to deliver greater volume and medical laboratory tests. CML is also working to commercialize early-stage technologies in medical diagnostics in partnership with an Ontario government agency known as MaRS Innovation.
Assunta Krehl

Publically private - Yonge Street Media - March 17, 2010 - 0 views

  •  
    Karl Martin turned a pure research project into a commercial venture set to change how we interact with the emerging "surveillance society" by improving personal privacy. U of T's Innovations and Partnerships Office and the MaRS Centre came on board to help these researchers patent their work and attain funding opportunities.
Assunta Krehl

Ontario Minister of Research and Innovation - BioscienceWorld - May 6, 2010 - 1 views

  •  
    Hon. John Milloy, Minister of Research and Innovation and Minister of Training, Colleges and Univesities, states "Ontario has big expectations and goals for the life sciences industry and commercialization." MaRS is an innovation centre in Toronto.
Assunta Krehl

Only one Ottawa firm participating in McGuinty's trade mission to Israel - The Ottawa C... - 0 views

  •  
    Premier Dalton McGuinty designed the trade mission to Israel in part as a means of understanding Israel's success in nurturing innovation and attracting venture capital. Of 38 companies and organizations taking part in Ontario's six-day life sciences trade mission to Israel, only two are from Ottawa, and only one is a local business. MaRS Innovation, an agency devoted to commercializing research from 14 Toronto academic institutions, has strengthened linkages in Toronto.
Assunta Krehl

Medical lab operator CML HealthCare outlines strategy for growth, innovation - Canadian... - 0 views

  •  
    CML HealthCare Inc is planning to automate it's current infrastructure to deliver greater volume and medical laboratory tests. CML is also working to commercialize early-stage technologies in medical diagnostics in partnership with an Ontario government agency known as MaRS Innovation.
Assunta Krehl

Automate to Market - The Scientist - January 2010 - 1 views

  •  
    The Scientist spoke with researchers who are automating and commercializing the latest technologies to aid life science work. Ameer Taha, founder, Certo Labs, Toronto and Veronika Litinski, health-care and life sciences practice lead at the MaRS Centre, a Toronto-based innovation cluster that engages researchers in commercializing their inventions were interviewed. Litinski states that "Before people start spending money on [developing] a product, we want them to think about the value chain and how the industry ecosystem is organized."
Assunta Krehl

Research improves performance of next-generation solar cell technology - Physorg - Sept... - 0 views

  •  
    As stated in the Psych org "Researchers from the University of Toronto (U of T), the King Abdullah University of Science & Technology (KAUST) and Pennsylvania State University (Penn State) have created the most efficient solar cell ever made based on collodial-quatum-dots...a technology licensing agreement has been signed by U of T and KAUST, brokered by MaRS Innovations (MI), which will will enable the global commercialization of this new technology." 
Assunta Krehl

U of T-led research improves performance of next-generation solar cell technology - Sci... - 0 views

  •  
    As stated in the Science Daily "Researchers from the University of Toronto (U of T), the King Abdullah University of Science & Technology (KAUST) and Pennsylvania State University (Penn State) have created the most efficient solar cell ever made based on collodial-quatum-dots...a technology licensing agreement has been signed by U of T and KAUST, brokered by MaRS Innovations (MI), which will will enable the global commercialization of this new technology." 
Assunta Krehl

Celebrating 90 Years of Insulin - University of Toronto - November 2, 2011 - 0 views

  •  
    MaRS Discovery has a new exhibit called Insulin: Toronto's Gift to the World.The exhibit is a joint effort of the Faculty of Medicine, the MaRS Discovery commercialization initiative and the University Health Network, a group of U of T teaching hospitals.
Assunta Krehl

Canadian discovers method to radically minimize scars - The Globe and Mail - May 7, 2012 - 0 views

  •  
    "MaRS Innovation (MI), The Hospital for Sick Children (SickKids) and NovoTek Therapeutics Inc. (NovoTek, Beijing/China) have announced a strategic partnership to co-develop a therapeutic cream aimed at reducing scar formation post surgery."
Assunta Krehl

Encycle Therapeutics Launches Ground-Breaking Chemistry Platform - MaRS Innovation - Ju... - 1 views

  •  
    "Encycle Therapeutics, a MaRS Innovation spin-off company, has created a ground-breaking chemistry platform for cyclizing peptides that promises to increase the efficiency of the early-stage drug discovery process."
Assunta Krehl

Diamond Schmitt Architects to design cancer research lab space at MaRS in Toronto - Dai... - 0 views

  •  
    "Diamond Schmitt Architects will design research laboratory space for the Ontario Institute for Cancer Research (OICR) at the MaRS Phase II west tower currently under construction in downtown Toronto." MaRS Phase II occupancy is slatted for 2013.
Cathy Bogaart

OGI Invests in Personalized Medicine for Age-related Macular Degeneration - November 1,... - 0 views

  •  
    The Ontario Genomics Institute has given funding to MaRS life sciences client, ArcticDX. They'll use the money for studies in preparation for a Food and Drug Administration approval for their product. The funding comes through its Pre-Commercialization Business Development Fund (PBDF)
1 - 18 of 18
Showing 20 items per page